Data Highlight Safety and Efficacy of CD101 IV and CD101 Topical
for the Treatment of Fungal Infections
SAN DIEGO –
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company
developing novel anti-infectives including immunotherapies, today
announced that data from preclinical and clinical studies evaluating its
novel echinocandin antifungal CD101 as a potential treatment for serious
infections will be presented at the 2016 American College of Clinical
Pharmacy (ACCP) Annual Meeting in Hollywood, Florida from October 23-26
and at the IDWeek 2016 meeting in New Orleans, Louisiana from October
26-30.
A total of five presentations will highlight the unique attributes of
CD101, Cidara’s lead antifungal drug candidate and the only long-acting
antifungal in the echinocandin class. In December 2015, the Infectious
Diseases Society of America (IDSA) issued new clinical guidelines
recommending a shift to echinocandins as first-line treatment for
invasive candidiasis and candidemia, serious infections that are often
fatal. Cidara is advancing two formulations of CD101 to address two
areas of high unmet need, both of which are currently in Phase 2
clinical trials.
“These presentations showcase the breadth and depth of our work to
advance CD101, a compound with demonstrated potential to address the
urgent unmet need for new and effective antifungal agents,” said Jeffrey
Stein, Ph.D., president and chief executive officer of Cidara. “New
solutions that address the unmet needs of and increasing resistance to
current standard-of-care treatments have become increasingly critical,
as demonstrated by the recent United Nations General Assembly
declaration that antimicrobial resistance is a major global health
issue. We are developing both IV and topical formulations of CD101 to
provide truly differentiated and broadly useful antifungal therapies
that will have multiple advantages over existing therapies.”
Details of the Cidara ACCP and IDWeek 2016 presentations are as follows:
ACCP 2016 Presentations
Tuesday, October 25: Scientific Poster Session IV – Original Research
(8:00 a.m. – 10:00 a.m. ET, Diplomat Resort & Spa, East/West Grand
Ballroom)
-
258: Safety and Pharmacokinetics of
Single and Multiple Doses of CD101 IV: Results from Two Phase 1
Dose-Escalation Studies; T. Sandison, et. al. -
261E: Pharmacological Basis of CD101
Efficacy: Exposure Shape Matters; E.A. Lakota, et. al.
IDWeek 2016 Presentations
Friday, October 28: Session 163 – Mycology – There’s a Fungus Among
Us: Treatment (12:30 p.m. – 2:00 p.m. ET, New Orleans Convention Center,
Poster Hall)
-
1625: Activity of a Long Acting
Echinocandin (CD101) and Comparator Antifungal Agents Tested Against
Contemporary Worldwide Invasive Fungal Isolates; M. Pfaller, et. al. -
1639: Efficacy of Topical CD101, a Novel
Echinocandin, Against Azole-Resistant Candida albicans in Rat
Vulvovaginal Candidiasis; V. Ong, et. al.
Saturday, October 29: Session 227 – Antimicrobial Pharmacokinetics
and Pharmacodynamics (12:30 p.m. – 2:00 p.m. ET, New Orleans Convention
Center, Poster Hall)
-
1994: PK-PD Target Attainment Analyses to
Support the Selection of Extended Interval CD101 Dosing Regimens; E.A.
Lakota, et. al.
Copies of these presentations and posters will be available on the
Cidara website following the meetings: http://www.Cidara.com/
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on developing
new anti-infectives that have the potential to transform the standard of
care and save or improve patients’ lives. The company is currently
advancing its novel echinocandin antifungal, CD101, through Phase 2
studies in two indications and developing CD201, its bispecific
antimicrobial immunotherapy, for the treatment of multi-drug resistant
bacterial infections. CD101 IV has enhanced potency and is the only
once-weekly therapy intended for the treatment and prevention of
life-threatening invasive fungal infections. CD101 topical is the first
and only agent of its class being studied for the treatment and
prevention of vulvovaginal candidiasis (VVC), a prevalent mucosal
infection. CD201 is the first drug candidate selected from Cidara’s
novel Cloudbreak™ platform, the first immunotherapy discovery platform
designed specifically to create compounds that direct a patient’s immune
cells to attack and eliminate bacterial, fungal or viral pathogens.
Cidara is headquartered in San Diego, California. For more information,
please visit www.cidara.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are
not historical facts are “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements regarding the effectiveness, safety, long-acting nature,
anticipated human dosing and other attributes of CD101 IV and CD101
topical, and their potential to treat infections, as well as the
intended design of current and future Cloudbreak compounds. Risks that
contribute to the uncertain nature of the forward-looking statements
include: the success and timing of Cidara’s preclinical studies and
clinical trials; regulatory developments in the United States and
foreign countries; changes in Cidara’s plans to develop and
commercialize its product candidates; Cidara’s ability to obtain
additional financing; Cidara’s ability to obtain and maintain
intellectual property protection for its product candidates; and the
loss of key scientific or management personnel. These and other risks
and uncertainties are described more fully in Cidara’s Form 10-Q most
recently filed with the United States Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Cidara
undertakes no obligation to update such statements to reflect events
that occur or circumstances that exist after the date on which they were
made.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161024005355/en/
INVESTORS:
Westwicke Partners, LLC
Robert H. Uhl,
858-356-5932
Managing Director
robert.uhl@westwicke.com
or
MEDIA:
Sam
Brown Inc.
Mike Beyer, 312-961-2502
mikebeyer@sambrown.com
